[PDF] Top 20 Gangrena de Fournier: revisión de factores determinantes de mortalidad
Has 10000 "Gangrena de Fournier: revisión de factores determinantes de mortalidad" found on our website. Below are the top 20 most common "Gangrena de Fournier: revisión de factores determinantes de mortalidad".
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
... of patients who present with metastatic disease, archival material from their primary tumour will not always be ...these patients, biomarker testing is usually carried out using specimens obtained ... See full document
6
Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
... for patients with metastatic colorectal cancer has substantially improved owing to the availability of new cytotoxic and biological agents along with many significant advances in molecular ... See full document
92
A Single Nucleotide Polymorphism in the MGMT Gene is a Novel Prognostic Biomarker in Patients with Metastatic Colorectal Cancer
... and management of metastatic colorectal cancer (mCRC), a disease with a median survival of 24-30 months ...when patients with stage II are treated with 5-FU adjuvant therapy ... See full document
23
Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016
... of patients such as advances in technology that provides closer follow-up of pre-malig- nant lesions, timely and more efficient ther- apies (especially second-line therapies) and increased number of ... See full document
12
Canadian consensus guidelines for the management of testicular germ cell cancer
... chemotherapy-naïve patients. These factors include: site of the primary cancer (gonadal better than non-gonadal); histology of the primary tumour (seminoma better than nonseminoma); response to first- line ... See full document
13
<p>Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives</p>
... neoadjuvant FOLFIRINOX for patients who may undergo resection of pancreatic cancer. This is a single institution phase I trial seeking to recruit 30 patients. Another phase II trial is comparing ... See full document
6
Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis
... of patients is ...thus patients might have been managed differently for similar ...MSI-H cancer patients. Our patient cohort consists mainly of patients referred to genetic counseling, ... See full document
6
Validation of Surrogate Endpoints in Advanced Solid Tumors: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers
... analysis. 1,3,6 Statistical analyses were often weighted by trial size. Three papers included a variety of first-line treatments, 1-3 and one included only second- or third-line treatments. 7 In studies that included ... See full document
41
Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement
... for management of recurrent or metastatic prostate cancer are based on available evidence and expert consensus regarding standards of current ... See full document
5
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
... Colorectal cancer is a disease of the elderly. As older and frail patients are under-represented in clinical trials, most of the evidence available on treatment of older metastatic ... See full document
101
Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer
... consecutive patients were enrolled in this study. Among these patients, 63 were males and 43 were females, with a median age of 52 years (range: 22–81 ...Seventy-two patients were treated with ... See full document
37
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
... A more accurate estimation of the impact of baseline characteristics on ePFS was obtained through the Kernel smoothed hazard estimator model to overcome the selec- tion bias introduced by the occurrence of liver resec- ... See full document
14
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
... Fruquintinib is a potent and highly selective small molecule inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine and has shown strong anti-tumor activity in various preclinical models [11, 12]. In phase I trials, ... See full document
465
<p>Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy</p>
... In any case, this issue was assessed by Shibutani et al 28 and found that there was a signi fi cant correlation between the BMI and psoas muscle mass index, which is recog- nized as a more dependable objective measure of ... See full document
53
Hospital Costs of Adverse Events in Patients with Metastatic Colorectal Cancer
... Adverse events (AEs) associated with mCRC treat- ments have the potential to impact healthcare resource utilisation and the overall cost of patient care [12]. How- ever, few studies have evaluated the direct costs ... See full document
56
Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
... were randomly divided into treatment group (thalidomide with XELOX) or control group (XELOX). The primary end point, PFS (5.6 vs 5.2 months, P = 0.307), and one secondary end point, ORR (34.1% vs 26.7%, P = 0.446), were ... See full document
7
Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy
... Twenty patients were enrolled in the clinical trial and pre- and post-treatment ...most patients received weekly 5FU/leucovorin though later, because of changes that occurred in the standard of care, the ... See full document
14
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
... of patients with different outcome following regorafenib ...lung-limited metastatic disease and a long history of metastatic disease (≥18 months) are significantly associated with better clinical ... See full document
17
Poorer prognosis in young female patients with non-metastatic colorectal cancer: a hospital-based analysis of 5,047 patients in China
... We acknowledge the limitations inherent in our study, which was performed in a single institution with a relatively short follow-up time. Young CRC patients ( ≤ 35 years old) only compose a small portion of the ... See full document
5
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
... the colorectal carcinogenesis, inactiva- tion of tumor suppressor PTEN could be potentially related to cetuximab ...to colorectal carcinogenesis, the activating mutations in KRAS are furthermore clearly ... See full document
12
Related subjects